V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320003552 | 320002151 | 1.7 | null | Adjuvant (A) | 2017-11-12 | 2017-09-17 | Cisplatin + Gemcitabine (D 1 & 8) | null | null | 320023106 | PEMBROLIZUMAB |
| 320003553 | 320002152 | 1.7 | null | Neo-adjuvant (N) | null | 2015-05-30 | BCG Intravesical | null | null | 320023113 | BCG |
| 320003554 | 320002153 | 1.66 | null | Neo-adjuvant (N) | 2013-03-20 | 2013-03-20 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 320023118 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003555 | 320002154 | 1.6 | 53.3 | Curative (C) | 2017-11-29 | 2017-12-14 | TCH (21 day Trastuzumab) Maint | N | N | 320023121 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003558 | 320002156 | 1.57 | null | Palliative (P) | 2015-05-01 | 2015-05-19 | CISPLATIN + ETOPOSIDE | N | N | 320023133 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003559 | 320002157 | 1.54 | 62.8 | Palliative (P) | 2018-02-12 | 2018-02-13 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | N | 320023136 | IPILIMUMAB + NIVOLUMAB |
| 320003560 | 320005036 | 1.54 | null | Palliative (P) | 2013-07-19 | 2013-08-05 | ECX | 02 | N | 320023140 | BEVACIZUMAB + CARBO |
| 320003561 | 320005036 | null | 56.3 | Neo-adjuvant (N) | 2015-02-05 | 2015-02-05 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | null | 320023140 | CETUXIMAB |
| 320003562 | 320002158 | null | null | Neo-adjuvant (N) | null | 2015-04-03 | CISPLATIN + GEMCITABINE | null | null | 320023143 | EVEROLIMUS |
| 320003563 | 320005037 | 1.73 | null | Neo-adjuvant (N) | null | 2015-05-15 | CHOP R - 21 days | null | null | 320023147 | NOT MATCHED |
| 320003564 | 320002159 | 0 | 85.6 | Neo-adjuvant (N) | 2015-07-28 | 2015-08-07 | Trial Unspecified | 02 | null | 320023154 | NOT MATCHED |
| 320003565 | 320002160 | 1.6 | 60.6 | Disease modification (D) | 2015-02-06 | 2015-02-13 | ICON8B TRIAL | 02 | N | 320023161 | CISPLATIN + DOCETAXEL |
| 320003566 | 320002161 | null | 56.9 | Adjuvant (A) | null | 2016-11-09 | CETUXIMAB + RT | null | null | 320023162 | PEMBROLIZUMAB |
| 320003567 | 320002162 | 1.7 | 80 | Neo-adjuvant (N) | 2015-08-12 | 2015-08-12 | CISPLATIN + GEMCITABINE | Y | null | 320023172 | MITOMYCIN INTRAVESICULAR |
| 320003568 | 320002163 | 1.75 | 50.1 | Neo-adjuvant (N) | 2015-10-06 | 2015-10-19 | MITOMYCIN | 02 | N | 320023173 | CARBO + FLUOROURACIL |
| 320003569 | 320002164 | 1.86 | 51.1 | Curative (C) | 2014-05-24 | 2014-06-14 | Cisplatin + Etoposide (3 day) | N | N | 320023188 | TEMOZOLOMIDE |
| 320003570 | 320002164 | 1.64 | 50.2 | Palliative (P) | 2017-12-12 | 2017-12-25 | Paclitaxel 7 day | 2 | N | 320023188 | PEMBROLIZUMAB |
| 320003571 | 320002165 | 1.56 | 18 | Curative (C) | 2016-12-05 | 2017-01-01 | Bevacizumab+Carbo+Gemcitabine | N | Y | 320023195 | ICON8B TRIAL |
| 320003572 | 320002166 | 1.73 | null | Palliative (P) | 2016-01-02 | 2016-01-09 | BCG Intravesical | 02 | N | 320023196 | ECX |
| 320003573 | 320002167 | 1.5 | 61 | Curative (C) | 2014-03-05 | 2014-03-26 | EC | N | N | 320023207 | CARBOPLATIN + ETOPOSIDE |
| 320003574 | 320002167 | 1.72 | 94.6 | Palliative (P) | 2016-09-18 | 2016-10-05 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320023207 | LANREOTIDE |
| 320003575 | 320002168 | 1.62 | 100 | Palliative (P) | 2018-02-10 | 2018-02-23 | ICON8 TRIAL | 02 | N | 320023216 | TEMOZOLOMIDE + RT |
| 320003576 | 320002169 | 1.57 | 65 | Curative (C) | 2018-10-26 | 2018-10-30 | Docetaxel + Trastuzumab (Maint) | 02 | Y | 320023226 | CAPECITABINE + CARBOPLATIN |
| 320003577 | 320002170 | 1.82 | 77.6 | Neo-adjuvant (N) | 2017-09-20 | 2017-09-21 | Carboplatin + Etoposide IV 3 day | N | N | 320023227 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 320003578 | 320005040 | 1.64 | 108.4 | Not known (9) | 2014-07-18 | 2014-07-18 | CISPLATIN + FLUOROURACIL + RT | Y | N | 320023235 | FLUOROURACIL |
| 320003579 | 320005040 | 1.62 | 0 | Curative (C) | 2015-11-29 | 2015-12-24 | Cetuximab +Cisplatin + FU (Cycle 1) | N | Y | 320023235 | CARBOPLATIN + LIPOSOMAL DOX |
| 320003580 | 320006953 | null | null | Neo-adjuvant (N) | null | 2015-01-31 | Cisplatin+Gemcitabine (Days 1&8&15) | null | N | 320023244 | IMATINIB |
| 320003581 | 320002171 | 1.68 | 58.2 | Palliative (P) | 2017-04-17 | 2017-04-23 | Capecitabine + Oxaliplatin 21day | Y | N | 320023245 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 320003582 | 320005041 | 1.58 | 70.2 | Palliative (P) | 2017-07-05 | 2017-07-16 | ECX | N | N | 320023251 | MITOMYCIN INTRAVESICULAR |
| 320003583 | 320006358 | 1.77 | 77 | null | 2014-10-04 | 2014-10-04 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 320023252 | DACARBAZINE |
| 320003584 | 320006358 | 1.58 | 49.8 | Palliative (P) | 2015-09-30 | 2015-11-20 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320023252 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320003585 | 320002172 | null | null | Curative (C) | 2013-08-08 | 2013-08-22 | Capecitabine + Mitomycin | Y | null | 320023257 | CARBOPLATIN + ETOPOSIDE |
| 320003586 | 320002173 | 1.71 | 68.75 | Adjuvant (A) | null | 2016-01-12 | Carbo F | N | Y | 320023259 | CAPECITABINE + OXALIPLATIN |
| 320003587 | 320002174 | 1.65 | 68.6 | Disease modification (D) | 2019-04-08 | 2019-04-08 | CNS LGG 2004 03 vinc weekly+ carbo | 2 | null | 320023270 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003588 | 320002175 | 1.75 | 109.6 | Palliative (P) | 2015-08-31 | 2015-11-28 | Bendamustine+Rituximab (1st Course) | 02 | N | 320023272 | ECX |
| 320003589 | 320002176 | 0 | 68.9 | Adjuvant (A) | 2013-08-18 | 2013-09-03 | CARBOPLATIN + RT | N | Y | 320023276 | CYCLOPHOSPHAMIDE |
| 320003590 | 320002176 | 1.66 | null | Palliative (P) | 2014-10-20 | 2014-11-04 | VIDE | N | N | 320023276 | CYCLOPHOSPHAMIDE |
| 320003591 | 320002177 | 1.51 | 60 | Palliative (P) | 2016-01-28 | 2016-02-01 | Ipilimumab | N | N | 320023284 | DOXORUBICIN |
| 320003592 | 320002178 | null | 105.4 | Curative (C) | 2018-06-23 | 2018-06-30 | Atezolizumab | 99 | N | 320023286 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003593 | 320002179 | 1.6 | 80.8 | Palliative (P) | 2017-12-08 | 2017-12-09 | CARBOPLATIN + ETOPOSIDE | 2 | N | 320023297 | CETUXIMAB + RT |
| 320003594 | 320002180 | 1.68 | 69.5 | Neo-adjuvant (N) | null | 2017-02-26 | Carboplatin + Liposomal Doxorubicin | null | null | 320023304 | CISPLATIN + GEMCITABINE |
| 320003595 | 320002181 | 1.6 | 88 | Palliative (P) | 2014-07-10 | 2014-07-11 | EOX | N | N | 320023311 | CISPLATIN + VINORELBINE |
| 320003596 | 320002182 | null | null | null | 2015-01-15 | 2015-01-28 | Irinotecan + Modified De Gramont | null | null | 320023313 | CAPECITABINE + CETUXIMAB + CISPLATIN |
| 320003597 | 320005043 | 1.63 | 79.9 | Adjuvant (A) | 2014-02-10 | 2014-02-24 | Cetuximab + Radiotherapy Maint | 02 | N | 320023318 | CAPECITABINE + OXALIPLATIN |
| 320003598 | 320005043 | 1.56 | null | Adjuvant (A) | 2013-10-04 | 2015-06-19 | Capecitabine + Oxaliplatin 21day | N | N | 320023318 | TRIAL |
| 320003599 | 320005043 | 1.61 | 59 | Disease modification (D) | 2018-01-25 | 2018-02-09 | Ipilimumab | Y | N | 320023318 | CISPLATIN + VINORELBINE + RT |
| 320003600 | 320005043 | null | null | Palliative (P) | 2016-02-05 | 2016-02-16 | CISPLATIN + GEMCITABINE | 02 | N | 320023318 | TRIAL |
| 320003601 | 320002183 | 1.63 | null | Adjuvant (A) | 2013-11-27 | 2013-12-04 | Cisplatin + Gemcitabine (D 1 & 8) | Y | N | 320023349 | CETUXIMAB |
| 320003602 | 320002184 | 1.61 | 63 | Curative (C) | 2014-02-02 | 2014-02-09 | Everolimus 5mg | N | N | 320023358 | POUT TRIAL |
| 320003603 | 320002185 | 1.85 | 48 | Curative (C) | 2013-09-30 | 2013-10-15 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | N | 320023361 | CTD |